103 related articles for article (PubMed ID: 8022755)
1. Beta-cell function in pancreatic adenocarcinoma.
Basso D; Plebani M; Fogar P; Del Favero G; Briani G; Meggiato T; Panozzo MP; Ferrara C; D'Angeli F; Burlina A
Pancreas; 1994 May; 9(3):332-5. PubMed ID: 8022755
[TBL] [Abstract][Full Text] [Related]
2. C-peptide pattern in patients with pancreatic cancer.
Fogar P; Basso D; Panozzo MP; Del Favero G; Briani G; Fabris C; D'Angeli F; Meggiato T; Ferrara C; Plebani M
Anticancer Res; 1993; 13(6B):2577-80. PubMed ID: 8135497
[TBL] [Abstract][Full Text] [Related]
3. [Clinical usefulness of the glucagon test in the study of pancreatic islet cell function].
Llorente I; Goñi MJ; Forga L; Monreal M; Lizcano F; Moncada E
Rev Med Univ Navarra; 1992; 37(1):25-9. PubMed ID: 1626165
[TBL] [Abstract][Full Text] [Related]
4. Basal and glucagon-stimulated plasma C-peptide concentrations in healthy dogs, dogs with diabetes mellitus, and dogs with hyperadrenocorticism.
Montgomery TM; Nelson RW; Feldman EC; Robertson K; Polonsky KS
J Vet Intern Med; 1996; 10(3):116-22. PubMed ID: 8743209
[TBL] [Abstract][Full Text] [Related]
5. Increased blood proinsulin and decreased C-peptide levels in patients with pancreatic cancer.
Nakamori S; Ishikawa O; Ohigashi H; Sasakuma F; Shimizu T; Nakaizumi A; Furukawa H; Sasaki Y; Imaoka S
Hepatogastroenterology; 1999; 46(25):16-24. PubMed ID: 10228759
[TBL] [Abstract][Full Text] [Related]
6. Lower plasma levels of glucose-dependent insulinotropic peptide (GIP) and pancreatic polypeptide (PP) in patients with ductal adenocarcinoma of the pancreas and their relation to the presence of impaired glucoregulation and weight loss.
Škrha J; Bušek P; Uhrová J; Hrabal P; Kmochová K; Laclav M; Bunganič B; Frič P
Pancreatology; 2017; 17(1):89-94. PubMed ID: 28027898
[TBL] [Abstract][Full Text] [Related]
7. C-peptide response to glucagon in young diabetics.
Juang JH; Huang BY; Huang HS; Lin JD; Huang MJ
Taiwan Yi Xue Hui Za Zhi; 1989 Jun; 88(6):579-83. PubMed ID: 2677232
[TBL] [Abstract][Full Text] [Related]
8. Improved glucose metabolism after subtotal pancreatectomy for pancreatic cancer.
Permert J; Ihse I; Jorfeldt L; von Schenck H; Arnquist HJ; Larsson J
Br J Surg; 1993 Aug; 80(8):1047-50. PubMed ID: 8402064
[TBL] [Abstract][Full Text] [Related]
9. Prolonged maximal stimulation of insulin secretion in healthy subjects does not provoke preferential release of proinsulin.
Nauck MA; Siegel EG; Creutzfeldt W
Pancreas; 1991 Nov; 6(6):645-52. PubMed ID: 1780324
[TBL] [Abstract][Full Text] [Related]
10. C-peptide response to glucagon in patients with non-insulin-dependent diabetes mellitus.
Juang JH; Huang HS; Huang MJ
J Formos Med Assoc; 1992 May; 91(5):491-6. PubMed ID: 1358326
[TBL] [Abstract][Full Text] [Related]
11. Plasma C-peptide and insulin responses to intravenous glucagon stimulation in idiopathic haemochromatosis.
Rumbak MJ; Joffe BI; Seftel HC; Kalk WJ; Bezwoda WR; Bothwell TH
S Afr Med J; 1987 Mar; 71(6):351-3. PubMed ID: 3551126
[TBL] [Abstract][Full Text] [Related]
12. [Clinical significance of measuring serum c-peptide before and after glucagon injection].
Kan Y; Chi Z
Zhonghua Yi Xue Za Zhi; 1991 Jan; 71(1):16-7, 4. PubMed ID: 1850647
[TBL] [Abstract][Full Text] [Related]
13. Intact proinsulin and beta-cell function in lean and obese subjects with and without type 2 diabetes.
Røder ME; Dinesen B; Hartling SG; Houssa P; Vestergaard H; Sodoyez-Goffaux F; Binder C
Diabetes Care; 1999 Apr; 22(4):609-14. PubMed ID: 10189540
[TBL] [Abstract][Full Text] [Related]
14. C-peptide response to glucagon. A test for the residual beta-cell function in diabetes mellitus.
Faber OK; Binder C
Diabetes; 1977 Jul; 26(7):605-10. PubMed ID: 326604
[TBL] [Abstract][Full Text] [Related]
15. Morphometric studies in human pancreatic cancer argues against the etiological role of type 2 diabetes in pancreatic cancer.
Saruc M; Iki K; Pour PM
Histol Histopathol; 2010 Apr; 25(4):423-32. PubMed ID: 20183795
[TBL] [Abstract][Full Text] [Related]
16. Pancreas and gut hormone responses to oral glucose and intravenous glucagon in cystic fibrosis patients with normal, impaired, and diabetic glucose tolerance.
Lanng S; Thorsteinsson B; Røder ME; Orskov C; Holst JJ; Nerup J; Koch C
Acta Endocrinol (Copenh); 1993 Mar; 128(3):207-14. PubMed ID: 8480468
[TBL] [Abstract][Full Text] [Related]
17. Pancreatic beta-cell function in cirrhotic patients with and without overt diabetes. C-peptide response to glucagon and to meal.
Marchesini G; Melli A; Checchia GA; Mattioli L; Capelli M; Cassarani S; Zoli M; Pisi E
Metabolism; 1985 Aug; 34(8):695-701. PubMed ID: 3894876
[TBL] [Abstract][Full Text] [Related]
18. Studies of pancreatic alpha cell function in normal and diabetic subjects.
Unger RH; Aguilar-Parada E; Müller WA; Eisentraut AM
J Clin Invest; 1970 Apr; 49(4):837-48. PubMed ID: 4986215
[TBL] [Abstract][Full Text] [Related]
19. Defective amplification of the late phase insulin response to glucose by GIP in obese Type II diabetic patients.
Vilsbøll T; Krarup T; Madsbad S; Holst JJ
Diabetologia; 2002 Aug; 45(8):1111-9. PubMed ID: 12189441
[TBL] [Abstract][Full Text] [Related]
20. Pancreatic hormone secretion in chronic pancreatitis without residual beta-cell function.
Larsen S; Hilsted J; Tronier B; Worning H
Acta Endocrinol (Copenh); 1988 Jul; 118(3):357-64. PubMed ID: 2899369
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
